(Q36612255)

English

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

scientific article published on 8 August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer (English)

1 reference

Europe PubMed Central

15 August 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

George Fountzilas

6

object named as

G Fountzilas

1 reference

Europe PubMed Central

15 August 2017

author name string

G P Stathopoulos

1

1 reference

Europe PubMed Central

15 August 2017

K Syrigos

2

1 reference

Europe PubMed Central

15 August 2017

G Aravantinos

3

1 reference

Europe PubMed Central

15 August 2017

A Polyzos

4

1 reference

Europe PubMed Central

15 August 2017

P Papakotoulas

5

1 reference

Europe PubMed Central

15 August 2017

A Potamianou

7

1 reference

Europe PubMed Central

15 August 2017

N Ziras

8

1 reference

Europe PubMed Central

15 August 2017

J Boukovinas

9

1 reference

Europe PubMed Central

15 August 2017

J Varthalitis

10

1 reference

Europe PubMed Central

15 August 2017

N Androulakis

11

1 reference

Europe PubMed Central

15 August 2017

A Kotsakis

12

1 reference

Europe PubMed Central

15 August 2017

G Samonis

13

1 reference

Europe PubMed Central

15 August 2017

V Georgoulias

14

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

8 August 2006

1 reference

Europe PubMed Central

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

15 August 2017

95

1 reference

Europe PubMed Central

15 August 2017

587-592

1 reference

Europe PubMed Central

15 August 2017

5

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603301

0 references

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Chemotherapy of adenocarcinoma of the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

30 September 2017

Gemcitabine: a new approach to treating pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

28 June 2018

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

20 September 2018

Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

20 September 2018

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

20 September 2018

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

20 September 2018

A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360678

20 September 2018

Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603301

1 reference

Europe PubMed Central

15 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36612255&oldid=1521364613"